Method of administration
OwnerAnne Claire Marrast, Wolfgang Fischerinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of mycophenolic acid, a salt or prodrug thereof in immunosuppression, particularly for prevention or treatment of transplant rejection and immune-mediated and/or inflammatory diseases, wherein mycophenolic acid, the salt or the prodrug thereof is administered with an initial intensified dosage regimen.
Claims9
1-7. (canceled)
A method for optimizing administration of MPA in a subject in need thereof, comprising administering to the subject MPA in form of an enteric coated composition containing MPA, salt or prodrug thereof at a dosage of up to about 3-fold the standard dosage of MPA during an initial period of treatment lasting from about one week to about three months, and then administering MPA at the standard daily dosage of MPA.
A method for providing a MPA treatment in a subject in need thereof, comprising administering MPA in form of an enteric coated composition containing MPA, salt or prodrug thereof to the subject at a dosage of up to about 3-fold the standard dosage of MPA during an initial period of treatment lasting from about one week to about three months, and then administering MPA at the standard daily dosage of MPA.
A method for inhibiting graft rejection or treating an autoimmune disease or disorder in a subject in need thereof, comprising administering MPA to the subject with a dosage of up to about 3-fold the standard daily dosage of MPA during an initial period of treatment lasting from about one week to about three months, and then administering MPA at the standard daily dosage of MPA, wherein MPA is administered as an enteric coated composition containing MPA, a salt or a prodrug thereof.
Dependencies are inferred from the claim text.